A Case of DEB-TACE Combined with Anlotinib for Treatment of Liver Metastasis from Retroperitoneal Leiomyosarcoma

Huiying Cui, Qiang Xu, Zhezhu Han, Songnan Zhang Department of Oncology, Yanbian University Hospital, Yanji, 133000, People’s Republic of ChinaCorrespondence: Songnan Zhang, Department of Oncology, The Affiliated Hospital of Yanbian University, No. 1327 Juzi Street, Yanji City, Jilin Province, 133000, People’s Republic of China, Email [email protected]: Retroperitoneal soft tissue sarcomas are characterized by a high rate of local recurrence and distal metastases. The optimal treatment for prolonged survival remains unknown.Case Presentation: This study reports a patient with leiomyosarcoma (LMS) diagnosed through postoperative recurrence with failed systemic chemotherapy. The patient underwent retroperitoneal tumor resection and surgical pathology showed LMS.A CT scan of the abdomen was performed one year after the surgical procedure, which revealed the presence of multiple intrahepatic metastases. Two cycles of systemic chemotherapy with a combination of doxorubicin and ifosfamide were performed, after which imaging assessment showed the intrahepatic lesions were significantly enlarged compared to prior ones. Considering the failure of systemic chemotherapy, the patient was treated with drug-eluting bead transarterial chemoembolization (DEB-TACE) eight times with simultaneous targeted therapy with anlotinib, and the disease control time reached 29 months.Conclusion: This case provides a new treatment option for patients with multiple liver metastases from retroperitoneal leiomyosarcoma, which is discussed in the context of this case.Keywords: DEB-TACE, retroperitoneal soft tissue sarcoma, leiomyosarcoma, targeted therapy